A Stage 1B1 Clear Cell Cervical Cancer Patient who fell Pregnant whilst Awaiting Fertility Sparring Surgery Managed with Neoadjuvant Chemotherapy to Arrest Disease Progression until Delivery at 36 Weeks Gestation
Clear cell adenocarcinoma of the cervix is associated with exposure to diethylstilboestrol (DES) in utero.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:We present a case of a 25 years old woman who presented to the gynaecological oncology unit before pregnancy with a histological and clinical diagnosis of cervical squamous cell carcinoma stage 1B1.
📊
Key Findings & Data:She received neoadjuvant chemotherapy and was delivered at 36 weeks and a caesarean radical hysterectomy and pelvic lymphadenectomy was done.
💡
Conclusion & Impact:Clear cell adenocarcinoma of the cervix is associated with exposure to diethylstilboestrol (DES) in utero.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
We present a case of a 25 years old woman who presented to the gynaecological oncology unit before pregnancy with a histological and clinical diagnosis of cervical squamous cell carcinoma stage 1B1. She desired fertility and hence an elective admission for vaginal trachelectomy (for fertility sparring) was planned. She fell pregnant whilst awaiting surgery and opted to continue with the pregnancy after counselling. She received neoadjuvant chemotherapy and was delivered at 36 weeks and a caesarean radical hysterectomy and pelvic lymphadenectomy was done. There is no disease recurrence after 2 years of follow up. This case highlights the challenges of prolonged waiting periods for surgery in our setting as well as the presentation of a rare histopathology of clear cell carcinoma. Clear cell adenocarcinoma of the cervix is associated with exposure to diethylstilboestrol (DES) in utero.
🔖
Cite This Article
MBODİ, L., NEL, C., MBATHA, N., MARİTZ, R., NTSHWANTİ, N., SMİTH, T. (2019). A Stage 1B1 Clear Cell Cervical Cancer Patient who fell Pregnant whilst Awaiting Fertility Sparring Surgery Managed with Neoadjuvant Chemotherapy to Arrest Disease Progression until Delivery at 36 Weeks Gestation. Eurasian Journal of Medicine and Oncology, Cilt: 3 - Sayı: 4, 289–292. https://ajindex.com/articles/125942
Fruscio R, Villa A, Chiari S, Vergani P, Ceppi L, Et al. Locatelli A. Delivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: A series of nine cases and literature review. Gynecologic Oncology 2012
192–7. 2. Reich et al. Clear cell carcinoma of the uterine cervix:pathology and prognosis in surgically treated stage IB-IIB disease in women not exposed in utero to diethylstilberol. Gynecol Oncol 2000
331–5. [CrossRef] 3. Herbst AL. Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstillberol (DES). Gynecol Oncol 2000
147–56. [CrossRef] 4. Kaminsky PF, Maier RC (1983). Clear cell adenocarcinoma of the cervix unrelated to diethylstillbetsrol exposure. Obstet Gynecol 1983
720–7. 5. An HJ et al. Prevalence of human papilloma virus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mo Pathol 2005
528–34. [CrossRef] 6. Amant F, Van Calsteren K, Halaska M.J, Beijenen J, Lagae L Et al. Gynecologic cancers in pregnancy: Guidelines of an international consensus meeting. International Journal of Gynecologic cancer. Volume 19, Number S1, May 2009. [CrossRef] 7. Agorastos T, Zafrakas M, Mastrominas M. Long-term followup after cervical cancer treatment and subsequent successful surrogate pregnancy: Case report. Reproductive BioMedicine Online Vol 19. No 2. 2009 250-251
www.rbmonline.com/Article/3987 on web 12 June 2009. [CrossRef] 8. Robova H, Halaska M.J, Pluta M, Skapa P, Matecha J Et al. Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecologic Oncology 2014
213–6. [CrossRef] 9. Jiang X, Jin Y, Li Y et al. Clear cell carcinoma of the uterine cervix:clinical characteristics and feasibility of fertility-preserving treatment. Oncotargets and Therapy 2014
111–6. 10. Di Saia P.J, Creasman W.T. Clinical Gynecologic Oncology. Eighth edition. 2012. Elsevier Saunders. Page 414–9. 11. Balleyguier C, Fournet C, Ben Hassen W, Zareski E, Morice P et al. Management of cervical cancer detected during pregnancy: role of magnetic resonance imaging. Clinical Imaging 2013
70–6. [CrossRef] 12. Dawood R, Instone M, Kehoe S. Neo-adjuvant chemotherapy for cervical cancer in pregnancy: a case report and literature review. European Journal of Obstetrics & Gynecology and Reproductive Biology 2013